Beruflich Dokumente
Kultur Dokumente
Industry: Drugs
Price: $45.99
Chaikin Power Gauge Report | Generated: Wed Feb 29 11:41 EST 2012 Power Gauge Rating
GILD - Bullish
The Chaikin Power Gauge Rating for GILD is bullish due to very bullish price/volume activity and strong earnings performance. Price and volume activity for GILD is very bullish which is indicated by positive Chaikin money flow and an increasing volume trend.
TM
Bullish
GILD Gilead Scien.. February 24, 2012
Chaikin Sentiment Gauge for GILD is bullish. There is currently a significant positive sentiment within news stories concerning GILD.
TM
The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.
High Potential
Neutral
Low Potential
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
www.chaikinpowertools.com
Financial Metrics
LT Debt/Equity Ratio
Neutral
GILD's financial metrics are neutral. The company yields a high return on shareholder's equity and is carrying too much long term debt relative to its industry group. The rank is based on a high long term debt to equity ratio relative to its industry group, high price to book value ratio, high return on equity and relatively high cash flow.
Return on Equity
Business Value
Valuation
Ratio Price/Book Price/Sales TTM 5.03 4.12
Returns
Ratio Return on Invest Return on Equity TTM 25.6% 45.4%
Earnings Performance
Earnings Growth
Bullish
GILD's earnings performance has been strong. The company is priced relatively low compared to next year's projected EPS and has a stable 5 year earnings trend. The rank is based on worse than expected earnings in recent quarters, a relatively low projected P/E ratio and consistent earnings over the past 5 years.
Earnings Surprise
Earnings Trend
Earnings Consistency
EPS Estimates
Factor Quarterly EPS Yearly EPS Factor 3-5 year EPS Actual EPS Prev $0.82 $3.62 Actual EPS Growth 23.24% EST EPS Current $0.92 $3.68 Est EPS Growth 14.57% Change +0.10 +0.06 Change -8.67
EPS Surprise
Estimate Latest Qtr 1 Qtr Ago 2 Qtr Ago 3 Qtr Ago $1.00 $0.96 $0.96 $0.92 Actual $0.92 $0.97 $0.95 $0.82 Difference $-0.08 $0.01 $-0.01 $-0.10 % Difference -8.00 1.04 -1.04 -10.87
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
www.chaikinpowertools.com
Very Bullish
Price and volume activity for GILD is very bullish. GILD is experiencing sustained buying and is trading on higher volume than its 90 day average volume. The rank for GILD is based on positive Chaikin money flow, a negative Chaikin price trend ROC and an increasing volume trend.
Price Trend
Volume Trend
Chart shows whether GILD is performing better or worse than the market.
Chaikin Money Flow analyzes supply and demand for a company's stock.
Price Activity
Factor 52 Week High 52 Week Low % Change YTD Rel S&P 500 Value 56.02 35.34 1.82%
Price Activity
Factor % Change Price - 4 Weeks % Change Price - 24 Weeks % Change Price - 4 Wks Rel to S&P % Change Price - 24 Wks Rel to S&P Value -5.85% 20.39% -9.95% 2.90%
Volume Activity
Factor Average Volume 20 Days Average Volume 90 Days Chaikin Money Flow Persistency Value 13,973,421 10,207,012 91%
Expert Opinions
Expert Opinions
Neutral
Expert opinions about GILD are neutral. Analysts's opinions on GILD have been more positive recently and analysts are lowering their EPS estimates for GILD. The rank for GILD is based on analysts revising earnings estimates downward, a low short interest ratio, insiders purchasing stock and optimistic analyst opinions.
Short Interest
Insider Activity
Analyst Opinions
Analyst Recommendations
Factor Mean this Week Mean Last Week Change Mean 5 Weeks Ago Value Buy Strong Buy +0.08 Strong Buy
Next Yr
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
www.chaikinpowertools.com
News Headlines for GILD U.S. FDA Grants Priority Review for Truvada for Reducing the Risk of Acquiring HIV Infection - Feb 13, 2012 Gilead Sciences jumps on hepatitis C data - Feb 3, 2012 Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Form - Jan 18, 2012 Gilead Sciences Completes Acquisition of Pharmasset, In - Jan 17, 2012 Gilead nears completion of Pharmasset deal Jan 12, 2012
Company Details Gilead Sciences 333 LAKESIDE DR FOSTER CITY, CA 94404 USA Phone: 6505743000 Fax: 650-578-9264 Website: http://http://www.gilead.com Full Time Employees: 4,000 Sector: Medical
Company Profile Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.